African regional progress and status of the programme to eliminate lymphatic filariasis: 2000–2020

To eliminate lymphatic filariasis (LF) by 2020, the World Health Organization (WHO) has launched a campaign against the disease. Since the launch in 2000, significant progress has been made to achieve this ambitious goal. In this article we review the progress and status of the LF programme in Africa through the WHO neglected tropical diseases preventive chemotherapy databank, the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) portal and other publications. In the African Region there are 35 countries endemic for LF. The Gambia was reclassified as not requiring preventive chemotherapy in 2015, while Togo and Malawi eliminated LF as a public health problem in 2017 and 2020, respectively. Cameroon discontinued mass drug administration (MDA) and transitioned to post-MDA surveillance to validate elimination. The trajectory of coverage continues to accelerate; treatment coverage increased from 0.1% in 2000 to 62.1% in 2018. Geographical coverage has also significantly increased, from 62.7% in 2015 to 78.5% in 2018. In 2019, 23 of 31 countries requiring MDA achieved 100% geographic coverage. Although much remains to be done, morbidity management and disability prevention services have steadily increased in recent years. Vector control interventions conducted by other programmes, particularly malaria vector control, have had a profound effect in stopping transmission in some endemic countries in the region. In conclusion, significant progress has been made in the LF programme in the region while we identify the key remaining challenges in achieving an Africa free of LF

Assessing Onchocerciasis Subcriticality from Pre-Intervention Cross-Sectional Surveys.

Elimination of an infectious disease requires subcritical transmission, or a reproductive number less than one, and can be assessed with cross-sectional surveys conducted by neglected tropical disease programs. Here, we assess the distribution of onchocerciasis prevalence taken from surveys across sub-Saharan Africa before the initiation of ivermectin in mass drug administrations. Pre-intervention nodular palpation cross-sectional surveys were available from 15 countries in the Expanded Special Project for Elimination of Neglected Tropical Diseases (ESPEN) database. We determined whether the distribution of the prevalence over communities in an area was consistent with a geometric distribution, which previous studies have suggested indicates a subcritical disease. If not, we fitted a negative binominal distribution (hypothetically supercritical) or a mixture of two distributions: geometric (hypothetically subcritical) and Poisson (hypothetically supercritical). The overall distribution of community-level onchocerciasis prevalence estimates from the ESPEN dataset from 2005 to 2014 was not consistent with a geometric distribution. By contrast, data from several countries and parts of countries were consistent with the geometric distribution, for example, some areas within Nigeria and Angola. Even if the geometric distribution suggested pre-intervention subcriticality in more localized geographical areas, our model using pooled survey data of all geographic areas suggests that the entire pre-intervention prevalence does not fit a geometric distribution. Further work will be required to confirm the significance of a geometric distribution for onchocerciasis

Schistosomiasis control in Senegal: results from community data analysis for optimizing preventive chemotherapy intervention with praziquantel

Abstract Background Over the past two decades, preventive chemotherapy (PC) with praziquantel (PZQ) is the major strategy for controlling schistosomiasis in Senegal. The objective of this analysis was to update the endemicity of schistosomiasis at community level for better targeting mass treatment with PZQ in Senegal. Methods Demographic and epidemiological data from 1610 community health areas were analyzed using the schistosomiasis community data analysis tool of Expanded Special Project for Elimination of Neglected Tropical Diseases which developed by World Health Organization/Africa Office (WHO/AFRO). The tool uses a WHO/AFRO decision tree for areas without epidemiological data to determine whether mass treatment should be continued at community level. Descriptive analysis was performed. Results Overall, the endemicity of 1610 community health areas were updated based on the data from the district endemicity (33.5%) and the form of Join request for selected PC medicine (40.5%). Up to 282 (17.5%) and 398 (24.7%) of community health areas were classified as moderate and high endemicity. 41.1% of communities were non endemic. High endemicity was more important in Tambacounda, Saint Louis, Matam, Louga and Kedougou. A change in endemicity category was observed when data was disagregted from district level to community level. Implementation units classified non endemic were more important at community level (n = 666) compared to district level (n = 324). Among 540 areas previously classified high endemic at district level, 392 (72.6%) remained high prevalence category, while 92 (17.0%) became moderate, 43 (8.0%) low and 13 (2.4%) non-endemics at community level. Number of implementation units requiring PC was more important at district level (1286) compared to community level (944). Number of school aged children requiring treatment was also more important at district level compared to community level. Conclusions The analysis to disaggregate data from district level to community level using the WHO/AFRO schistosomiasis sub-district data optimization tool provide an update of schistosomiasis endemicity at community level. This study has allowed to better target schistosomiasis interventions, optimize use of available PZQ and exposed data gaps